AlphaCentric Advisors’s Axsome Therapeutics AXSM Stock Holding History

AlphaCentric Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6M	Buy	6,531 +93	+1%	+$20.2K	1.35%	9
2026 Q1	$1.09M	Buy	6,438 +350	+6%	+$60.5K	1.09%	17
2025 Q4	$1.11M	Buy	+6,088	New	+$850K	1.11%	16
2024 Q4	–	Sell	-10,500	Closed	-$944K	–	217
2024 Q3	$944K	Sell	10,500 -4,500	-30%	-$393K	0.7%	50
2024 Q2	$1.21M	Sell	15,000 -17,500	-54%	-$1.3M	0.89%	37
2024 Q1	$2.59M	Buy	+32,500	New	+$2.73M	1.56%	14
2021 Q4	–	Sell	-23,000	Closed	-$758K	–	224
2021 Q3	$758K	Buy	23,000 +11,000	+92%	+$429K	0.19%	47
2021 Q2	$810K	Buy	12,000 +2,000	+20%	+$120K	0.22%	36
2021 Q1	$566K	Buy	+10,000	New	+$703K	0.19%	40

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AlphaCentric Advisors's AXSM Position: Q2 2026 in Review

AlphaCentric Advisors increased its Axsome Therapeutics (AXSM) stake by 1.4% in Q2 2026, buying an estimated $20.2K and bringing the position to 6,531 shares worth $1.6M. The position accounts for 1.35% of the portfolio, ranked #9.

AlphaCentric Advisors first reported a position in AXSM in Q1 2021 and has held it in 9 quarters since. The position peaked at $2.59M in Q1 2024. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

AlphaCentric Advisors held 6,531 shares of Axsome Therapeutics worth $1.6M as of Q2 2026.
AlphaCentric Advisors bought 93 Axsome Therapeutics shares in Q2 2026, an estimated $20.2K.
Axsome Therapeutics made up 1.35% of AlphaCentric Advisors's portfolio in Q2 2026, its #9 holding.
AlphaCentric Advisors first reported a position in Axsome Therapeutics in Q1 2021 and has held it in 9 quarters since.
AlphaCentric Advisors's Axsome Therapeutics position peaked at $2.59M in Q1 2024.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.